Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Christopher G. Willett, Emmanuelle di Tomaso(Bayer (United States)), Dan G. Duda(Harvard University), Yves Boucher(Harvard University), Gregory Y. Lauwers(Moffitt Cancer Center), Johanna Lahdenranta(Harvard University), Paul C. Shellito(Harvard University), Marek Ancukiewicz(Bridge University), Alan J. Fischman(Shriners Hospitals for Children), Martin Poleski(Duke Medical Center), Brian G. Czito(Harvard University), Dushyant V. Sahani(Brigham and Women's Hospital), Rex C. Bentley(Duke University), Terence Z. Wong(Harvard University), Daniel C. Chung(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Željko Vujašković(Harvard University), Helen X. Chen(National Cancer Institute), Erik K. Paulson(Duke University)
Cited by 507
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k
The Chromosomal Instability Pathway in Colon Cancer
|Gastroenterology|2010|932